Medicare Rebates On Drug ‘Wastage’: New Products Get Limited Time Reprieve
Regulation from CMS may drive manufacturers to repackage Medicare Part B drugs sold in single-use containers to avoid waste that would be subject to new rebate.
You may also be interested in...
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.
With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.
A new Medicare rebate for discarded portions of single-use vials is taking effect as scheduled in January – but the first invoices won’t be issued in the fall as planned. CMS says it wants to wait to ‘align’ the collections process with the new inflation rebates enacted by the IRA.